^
    Back
    Association details:
    Biomarker:EGFR mutation + BRAF V600
    Cancer:Lung Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tagrisso (osimertinib) (EGFR inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Lung Cancer
    Title:

    Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF V600 mutation as an acquired resistance mechanism

    Published date:
    07/20/2021
    Excerpt:
    ...a patient with EGFR mutated lung adenocarcinoma developing a BRAF V600 mutation as an acquired resistance mechanism...We present the case of a patient developing a BRAFV600 mutation as acquired resistance mechanism to osimertinib, who responded favorably to the combination of dabrafenib, trametinib and osimertinib.
    DOI:
    10.1016/j.lungcan.2021.06.025